ClinicalTrials.gg
CompletedNCT05161845Updated Aug 14, 2023

Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live

A Phase 4 interventional study of Measles, Mumps and Rubella Combined Vaccine, Live in Immunotoxicity and Vaccine, sponsored by Shanghai Institute Of Biological Products. Completed at 1 site in China. Open to participants aged 8 Months to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-14.

Sponsored by Shanghai Institute Of Biological Products (part of Sinopharm) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,068
Allocation
Not applicable
Ages
8 Months to 12 Months
Sex
All
01

Study summary

To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.

Read the detailed description

To assess Measles Mumps and Rubella Combined Vaccine, Live, (MMR) lot-to-lot consistency in healthy Chinese Children at the age of 8-12 months, and the participants randomized to receive one injections of 0.5 mL Measles, Mumps and Rubella Combined Vaccine, Live at day 0.

02

Conditions studied

  • Immunotoxicity
  • Vaccine

Keywords

  • MMR Combined Vaccines
  • safety
  • immunogenicity
03

In context

Lead sponsor

Shanghai Institute Of Biological Products is the lead sponsor of 34 studies on the registry; 14 are open to participants now.

First submitted after Shanghai Institute Of Biological Products became part of Sinopharm.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Months to 12 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Provide vaccination certificate and birth certificate for healthy children aged 8-12 months;

  • Volunteers' legal guardian , volunteered to participate and signed an informed consent form;
  • The volunteer's legal guardian has the ability to understand the research procedures, use the thermometer, scale and fill in the diary card as required, and can complete the clinical study in accordance with the requirements of the clinical trial protocol.

Exclusion criteria

Exclusion Criteria:

  • The axillary body temperature on the day of enrollment was more than 37.0 ℃;
  • Have suffered from measles, mumps and rubella in the past or are suffering from measles, mumps and rubella;
  • Any previous vaccination containing measles, mumps and rubella;
  • Persons known to be allergic to any ingredient in the vaccine;
  • Any previous history of vaccine or drug allergy;
  • Premature (delivered before the 37th week of pregnancy) and low weight (birth weight \< 2500g);
  • History of dystocia, asphyxia rescue and nervous system damage;
  • Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc;
  • Acute disease, serious chronic disease or acute attack of chronic disease on the day of vaccination;
  • Have a history of within 28 days before vaccination and other vaccines within 7 days;
  • Those who receive immune enhancement or inhibitor treatment within 3 months (continuous oral or drip for more than 14 days);
  • Suffering from congenital or acquired immunodeficiency, infection, lymphoma, leukemia or other diseases;
  • History of asthma, unstable in the past two years, requiring emergency treatment, hospitalization, intubation, oral or intravenous ;
  • Have received blood or blood related products;
  • Patients with progressive nervous system diseases have a history of convulsion, epilepsy, encephalopathy, GuillainBarre syndrome, mental history or family history;
  • Have a history of abnormal coagulation function (such as coagulation factor deficiency and coagulation diseases);
  • Plan to move out before the end of the study or leave for a long time during the scheduled study visit;
  • Participating in or planning to participate in other clinical trials in the near future;
  • The investigator judges any situation that is not suitable to participate in this clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,068 participants (actual)

Study arms

  • Experimental
    Experimental group

    Participants randomized to receive one injections of 0.5 mL Measles, Mumps and Rubella Combined Vaccine, Live at Day 0.

    Biological: Measles, Mumps and Rubella Combined Vaccine, Live

Interventions

  • BiologicalMeasles, Mumps and Rubella Combined Vaccine, Live

    0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.

06

What researchers measure

Primary outcomes

  1. The geometric mean concentrations (GMC)

    GMC of measles, mumps and rubella antibodies should be compared 42 days after vaccination, and detected by enzyme-linked immunosorbent assay (ELISA).

    Time frame: 42 days

Secondary outcomes

  1. The positive conversion rate of antibodies

    1. The positive conversion rate of antibodies to measles, mumps and rubella in each group 42 days after vaccination.The seroconversion rate refers to the proportion of subjects whose serum antibodies are negative before vaccination, which turn positive after vaccination, or serum antibodies are positive before vaccination, which increased by 4 times or more after vaccination.

    Time frame: 42 days

  2. The Seropositivity rate

    The seroprevalence rate refers to the proportion of subjects whose serum antibodies are positive. The cut-off for seropositivity for the antibody titers is as follows: 1. Anti-measles IgG antibody concentration by ELISA of \>200 mIU/mL. 2. Anti-mumps IgG antibody concentration by ELISA of \>100 U/mL. 3. Anti-rubella IgG antibody concentration by ELISA of \>20 IU/mL

    Time frame: 42 days

  3. The incidence of adverse events within 14 days

    The incidence of adverse events within 14 days after vaccination

    Time frame: 14 days

  4. All adverse events

    All adverse events from day 0 to 42 after vaccination

    Time frame: 42 days

  5. Serious adverse events

    Serious adverse events within 6 months after vaccination

    Time frame: 180 days

07

Study locations

1 site
  • Jiangsu Provincial Center for Disease Control and Prevention
    Nanjing, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Apr 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2021
First posted
Dec 17, 2021
StartActual
Dec 23, 2021
Primary completionActual
Apr 4, 2022
CompletionActual
Oct 1, 2022
Last update
Aug 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05161845
Responsible party
Sponsor
First posted
Dec 17, 2021
Start date
Dec 23, 2021
Primary completion
Apr 4, 2022
Completion
Oct 1, 2022
Last update
Aug 14, 2023

Study contacts

Hongxing Pan
principal investigator · Jiangsu Provincial Center for Disease Prevention and Control

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion